INCY
INCYTE CORP
Nasdaq: INCY · Wilmington, DE · Healthcare
$115.71-1.22 (-1.04%)Closed
Market Cap$23.14B
Cash$3.75Bmost recent
Runwayprofitable
P/E (TTM)18.1EPS $6.41
52-Wk Range$90.18 – $129.93
Avg Volume1.8M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$115.71+77.4%
Pipeline
Drug candidates sponsored by INCYTE · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | ruxolitinib cream | Atopic Dermatitis+8 more | Recruiting | 2026-12-09 | 16 | |
| Phase 3 | ruxolitinib tablets | Polycythemia Vera | Completed | 2014-01-15past | 1 | |
| Phase 3 | Nivolumab | Lung Cancer | Terminated | 2018-05-22past | 1 | |
| Phase 3 | Pembrolizumab | Head and Neck Cancer+2 more | Completed | 2018-12-13past | 3 | |
| Phase 3 | Ruxolitinib | MPN (Myeloproliferative Neoplasms)+3 more | Completed | 2020-05-08past | 4 | |
| Phase 3 | Placebo | COVID-19 | Terminated | 2021-02-26past | 1 | |
| Phase 3 | parsaclisinib | Warm Autoimmune Hemolytic Anemia (wAIHA) | Terminated | 2023-10-17past | 1 | |
| Phase 2 | Itacitinib | Chronic Graft-versus-host Disease+5 more | Completed | 2023-11-03past | 5 | |
| Phase 3 | Retifanlimab | Non-small Cell Lung Cancer+11 more | Completed | 2024-05-22past | 8 | |
| Phase 2 | Rituximab (RTX) | Diffuse Large B-cell Lymphoma | Completed | 2024-06-21past | 1 | |
| Phase 3 | INCA034176 | Chronic Graft-versus-host-disease | Active, not recruiting | 2025-08-06past | 1 | |
| Phase 3 | Povorcitinib | Hidradenitis Suppurativa (HS)+2 more | Active, not recruiting | 2026-10-19past | 4 | |
| Phase 3 | parsaclisib | Follicular Lymphoma ( FL)+4 more | Completed | 2028-12-20 | 5 | |
| Phase 3 | Pemigatinib | Unresectable Cholangiocarcinoma+15 more | Not yet recruiting | 2031-02-25 | 6 | |
| Phase 2 | INCB018424 | Rheumatoid Arthritis | Completed | 2008-09past | 1 | |
| Phase 2 | Capecitabine | Pancreatic Cancer | Completed | 2013-06past | 1 | |
| Phase 2 | Placebo Cream | Alopecia Areata | Terminated | 2017-10-03past | 1 | |
| Phase 1 | INCB054329 Monotherapy | Solid Tumors and Hematologic Malignancy | Terminated | 2018-01-31past | 1 | |
| Phase 1 | INCB057643 | Solid Tumors | Terminated | 2019-02-13past | 1 | |
| Phase 1 | INCB052793 | Solid Tumors+2 more | Terminated | 2019-02-27past | 1 | |
| Phase 1 | INCAGN01876 | Advanced Malignancies+1 more | Completed | 2019-12-16past | 1 | |
| Phase 2 | Ponatinib | Philadelphia Positive+2 more | Completed | 2020-04-24past | 1 | |
| Phase 1 | Epacadostat | Solid Tumors+2 more | Terminated | 2021-01-29past | 2 | |
| Phase 1 | INCB001158 | Relapsed or Refractory Multiple Myeloma | Terminated | 2022-04-05past | 1 | |
| Phase 1 | INCB059872 | Solid Tumors and Hematologic Malignancy+1 more | Terminated | 2022-04-14past | 2 | |
| Phase 2 | INCB054707 | Prurigo Nodularis+2 more | Completed | 2024-02-07past | 2 | |
| Phase 2 | INCB086550 | Non Small Cell Lung Cancer+6 more | Completed | 2024-03-26past | 3 | |
| Phase 1 | tafasitamab | Chronic Lymphocytic Leukemia+1 more | Terminated | 2024-10-22past | 1 | |
| Phase 1 | INCB099280 | Advanced Solid Tumors+12 more | Completed | 2025-06-06past | 2 | |
| Phase 2 | Axatilimab | Chronic Graft-versus-host-disease+1 more | Active, not recruiting | 2026-10-01past | 2 | |
| Phase 2 | INCB123667 | Ovarian Cancer+3 more | Recruiting | 2027-04-13 | 3 | |
| Phase 1 | INCB000928 | Myelodysplastic Syndromes+5 more | Recruiting | 2027-07-30 | 3 | |
| Phase 2 | Dexelvucitabine | HIV Infections+1 more | Terminated | — | 1 | |
| Phase 1 | INCB053914 | Relapsed Diffuse Large B-Cell Lymphoma+1 more | Completed | 2020-09-01past | 1 | |
| Phase 1 | INCAGN02385 | Cervical Cancer+16 more | Completed | 2020-10-07past | 1 | |
| Phase 1 | INCB160058 | Healthy Participants | Completed | 2025-08-19past | 1 | |
| Phase 1 | INCB000631 | Healthy Participants | Terminated | 2025-10-11past | 1 | |
| Phase 1 | INCA033989 | Healthy Participants | Recruiting | 2026-10-19past | 1 | |
| Phase 1 | INCB186748 | Solid Tumors | Active, not recruiting | 2027-03-27 | 1 | |
| Phase 1 | INCA035784 | Myeloproliferative Neoplasms | Recruiting | 2028-03-14 | 1 | |
| Phase 1 | INCA036978 | Myeloproliferative Neoplasms | Recruiting | 2030-05-24 | 1 | |
| N/A | Unnamed | MPN (Myeloproliferative Neoplasms) | Completed | 2019-08-03past | 1 | |
| N/A | Unnamed | BCR-ABL Positive Acute Lymphoblastic Leukemia | Withdrawn | 2021-03past | 1 | |
| N/A | Unnamed | Chronic Phase Chronic Myelogenous Leukemia+3 more | Completed | 2021-03-31past | 1 | |
| N/A | Unnamed | MPN (Myeloproliferative Neoplasms) | Completed | 2022-03-29past | 1 | |
| N/A | Unnamed | Atopic Dermatitis+1 more | Completed | 2025-12-19past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for INCY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.